Surface Ophthalmics Announces Positive Top-Line Phase II Results
Surface Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity® vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation. Investigational therapy SURF-201 met all primary endpoints for the treatment of pain and inflammation following cataract surgery.